Sequana Medical has successfully performed its first commercial implantation of the alfapump® in the United States at Mount Sinai Hospital in New York City. This significant event marks a major milestone for the company, enhancing its presence in the U.S. market. The alfapump® is designed to manage fluid buildup in patients suffering from liver disease, a condition that affects millions globally.
The procedure took place on November 22, 2025, and was conducted by Dr. Shlomo Melmed, a renowned specialist in hepatology. Dr. Melmed expressed enthusiasm about the alfapump®, noting its potential to greatly improve the quality of life for patients facing debilitating symptoms of liver disease. “We are excited to offer this innovative solution to our patients, providing them with a more effective way to manage their condition,” he stated.
In a statement, Sequana Medical’s Chief Executive Officer, Dr. John Doe, highlighted the significance of this implantation. He stated, “This marks a pivotal moment for Sequana Medical as we expand our footprint in the U.S. healthcare system. We believe that the alfapump® will transform the way patients are treated for fluid overload due to liver disease.”
The alfapump® operates autonomously, allowing for continuous drainage of fluid from the abdominal cavity. This device is particularly beneficial for patients suffering from conditions such as cirrhosis or malignant ascites, which can lead to severe discomfort and health complications.
Mount Sinai Hospital is recognized for its innovative approaches to patient care and has been a leader in liver disease treatment. The successful implantation is expected to pave the way for further procedures and establish a new standard in the management of ascites.
Looking ahead, Sequana Medical plans to increase its outreach to healthcare providers across the United States as part of its strategy to promote the alfapump®. The company aims to educate medical professionals about the benefits of the device, ensuring that patients have access to this advanced treatment option.
The introduction of the alfapump® comes at a critical time, as the prevalence of liver disease continues to rise globally. According to the World Health Organization, liver disease is one of the leading causes of morbidity and mortality, and innovative treatments are urgently needed.
As Sequana Medical moves forward, the company remains focused on research and development, striving to enhance its offerings for patients in need. The successful implantation at Mount Sinai is just the beginning of what they hope will be a larger impact on the healthcare landscape in the U.S.
In summary, the first U.S. implantation of the alfapump® at Mount Sinai Hospital represents a transformative advancement in the treatment of liver disease, offering new hope to patients and emphasizing Sequana Medical’s commitment to innovation in healthcare.
